• Roche unit Genentech secured FDA approval for Enspryng to treat adults with thyroid eye disease.
• Enspryng becomes the first and only at-home subcutaneous treatment for the condition, administered by patients or caregivers following training.
• In SatraGO-2, proptosis response reached 52.9% with Enspryng versus 23.4% with placebo among patients with active disease.
• Diplopia reduction in that population reached 60.7% with Enspryng versus 25.8% with placebo.
• SatraGO-1 missed its prespecified primary efficacy endpoint at week 24; neither trial identified new safety signals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261015174934) on October 16, 2026, and is solely responsible for the information contained therein.